𝔖 Bobbio Scriptorium

✦ LIBER ✦

Preclinical rationale for a combined treatment with irinotecan and the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (Iressa) in irinotecan-refractory human colon cancer

Book ID: 117659869
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 157 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)81180-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epidermal growth factor receptor tyrosin

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (‘Iressa’), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in advanced colorectal cancer (ACRC)

✍ L. Hammond; J. Figueroa; L. Schwartzberg; L. Ochoa; M. Hidalgo; N. Olivo; G. Sch 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 346 KB

880 Prostate cancer cell proliferation i

880 Prostate cancer cell proliferation is strongly reduced by combination treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’) and the anti -androgen bicalutamide (‘casodex’)

✍ M. Bologna; A. Angelucci; C. Festuccia; G.L. Gravina; P. Muzi; C. Vicentini 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 166 KB

Antitumor activity of the epidermal grow

Antitumor activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘lressa’), alone or combined with gemcitabine and vinorelbine platinum-based chemotherapy, in human non-small-cell lung cancer (NSCLC) xenografts

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 132 KB

ZD1839 (‘Iressa’), an orally-active, sel

ZD1839 (‘Iressa’), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: preliminary tolerability, efficacy and pharmacokinetic results

✍ G. Giaccone; J.L. Gonzales-Larriba; E.F. Smit; A.T. van Oosterom; M. Martins; G. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 338 KB

Combining the epidermal growth factor re

Combining the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, ZD1839, with a selective cyclooxygenase (COX)-2 inhibitor, SC236, causes a cooperative antitumor effect in breast cancer cells derived from HER2/neu mice

✍ F.E. Rosato Jr; A. Dicker; R. Burd; S. Miller; S. Lanza-Jacoby 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 37 KB